Vertaling van "drugs in its pipeline that have promise " (Nederlands → Frans) :

Novartis has several other drugs in its pipeline that have promise for patients with unmet needs.
Novartis possède plusieurs autres médicaments dans son pipeline qui répondent aux besoins non satisfaits des malades.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Luckily for Shawn, Novartis wants to provide Glivec to patients who would otherwise not have access to it. Through its Glivec International Patient Assistance Program (GIPAP), Novartis has made it possible for the young South African to have a continual supply of the drug that has saved his life.
Avec sa campagne mondiale d’assistance aux malades (Glivec International Patient Assistance Program GIPAP), Novartis a permis au jeune Sud-Africain de recevoir de manière ininterrompue le médicament qui a sauvé sa vie.